NO20074407L - Oral doseringsform omfattende rosiglitazon - Google Patents

Oral doseringsform omfattende rosiglitazon

Info

Publication number
NO20074407L
NO20074407L NO20074407A NO20074407A NO20074407L NO 20074407 L NO20074407 L NO 20074407L NO 20074407 A NO20074407 A NO 20074407A NO 20074407 A NO20074407 A NO 20074407A NO 20074407 L NO20074407 L NO 20074407L
Authority
NO
Norway
Prior art keywords
dosage form
oral dosage
composition
rosiglitazone
layer
Prior art date
Application number
NO20074407A
Other languages
English (en)
Inventor
Vincenzo Re
Joanne Heafield
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20074407L publication Critical patent/NO20074407L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet en oral doseringsform med en tolags tablett, omfattende et første lag av en første sammensetning og et andre lag av en andre sammensetning, hvor hver sammensetning omfiatter 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion eller et fiarmasøytisk akseptabelt salt eller solvat derav ("legemidlet") og en fiarmasøytisk akseptabel bærer fior dette. Den fiørste og den andre sammensetningen er anordnet fior å firigi legemiddel ved fiorskjellige firigivelsesrater ved administrering. Oppfinnelsen gjelder også fior en fremgangsmåte fior firemstilling av en slik doseringsfiorm og anvendelse av en slik doseringsfiorm innen medisin.
NO20074407A 2005-02-07 2007-08-29 Oral doseringsform omfattende rosiglitazon NO20074407L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502475.7A GB0502475D0 (en) 2005-02-07 2005-02-07 Novel compositions
PCT/EP2006/000997 WO2006087116A1 (en) 2005-02-07 2006-02-03 Oral dosage form comprising rosiglitazone

Publications (1)

Publication Number Publication Date
NO20074407L true NO20074407L (no) 2007-08-29

Family

ID=34355898

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074407A NO20074407L (no) 2005-02-07 2007-08-29 Oral doseringsform omfattende rosiglitazon

Country Status (16)

Country Link
US (1) US20080166408A1 (no)
EP (1) EP1855671A1 (no)
JP (1) JP2008543723A (no)
KR (1) KR20070110016A (no)
CN (1) CN101155586A (no)
AU (1) AU2006215854A1 (no)
BR (1) BRPI0607803A2 (no)
CA (1) CA2595411A1 (no)
EA (1) EA200701681A1 (no)
GB (1) GB0502475D0 (no)
IL (1) IL184790A0 (no)
MA (1) MA29281B1 (no)
MX (1) MX2007009492A (no)
NO (1) NO20074407L (no)
TW (1) TW200700063A (no)
WO (1) WO2006087116A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
KR20110052641A (ko) * 2008-07-18 2011-05-18 베일언트 파마슈티컬스 인터내셔널 변형 방출형 제형 및 이의 이용 방법
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CA2848798C (en) * 2012-02-22 2014-12-23 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
HUE039131T2 (hu) 2013-07-22 2018-12-28 Duchesnay Inc Hányinger és hányás kezelésére szolgáló készítmény
TWI595874B (zh) 2014-08-29 2017-08-21 達契斯奈股份有限公司 多西拉敏及吡哆醇及／或其代謝產物或鹽之多模式釋放調配物
CA3172668A1 (en) * 2017-10-25 2019-05-02 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
UY28457A1 (es) * 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations

Also Published As

Publication number Publication date
GB0502475D0 (en) 2005-03-16
BRPI0607803A2 (pt) 2009-06-13
CN101155586A (zh) 2008-04-02
US20080166408A1 (en) 2008-07-10
AU2006215854A1 (en) 2006-08-24
WO2006087116A1 (en) 2006-08-24
TW200700063A (en) 2007-01-01
MA29281B1 (fr) 2008-02-01
JP2008543723A (ja) 2008-12-04
EP1855671A1 (en) 2007-11-21
EA200701681A1 (ru) 2007-12-28
IL184790A0 (en) 2007-12-03
CA2595411A1 (en) 2006-08-24
MX2007009492A (es) 2007-09-19
KR20070110016A (ko) 2007-11-15

Similar Documents

Publication Publication Date Title
NO20074407L (no) Oral doseringsform omfattende rosiglitazon
EA200701680A1 (ru) Лекарственная форма для перорального введения, содержащая розиглитазон
HUP0301161A2 (hu) Az 5-[4-[2-[N-metil-N-(2-piridil)-amino]-etoxi]-benzil]-tiazolidin-2,4-dion-maleát új polimorf formái és eljárás azok előállítására
EA200702648A1 (ru) Фармацевтическая композиция, пригодная для введения один раз в день
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
YU16303A (sh) Tartaratne soli derivata tiazolidindiona
DK1349855T3 (da) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
NO20076517L (no) Natriumsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksyl]benzyl]tiazolidin-2,4-dion
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
NO20075507L (no) Tiazolidindionderivater og deres anvendelse som antidiabetiske midler
AP1785A (en) Tartrate salt of thiazolidinedione derivative.
RS50130B (sr) Farmaceutska kompozicija 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil) tiazolidin-2,4-diona
AP2002002673A0 (en) Thiazolidinedione salt for the treatment of diabetes mellitus.
AP2003002737A0 (en) Tartrate salts of thiazolidinedione derivatives
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
JP2006528206A5 (no)
Weber et al. In vitro studies and computer simulation of interactions between R483, a novel thiazolidinedione, and cytochrome P450 substrates
TH85149B (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน
TH84984B (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน
DK1448559T3 (da) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolodin-2,4-dionbenzensulfat; fremgangsmåde til dets fremstilling; polymorf i, II og III deraf; og dets anvendelse som farmaceutisk aktiv bestenddel
TH85149A (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application